Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,876
edits
Changes
HAEM5:Acute basophilic leukaemia (view source)
Revision as of 14:16, 13 December 2023
, 14:16, 13 December 2023no edit summary
{{Under Construction}}
{{Under Construction}}
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Acute Basophilic Leukemia]].
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Acute Basophilic Leukemia]].
}}</blockquote>
}}</blockquote>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
==Primary Author(s)*==
==Primary Author(s)*==
==Definition / Description of Disease==
==Definition / Description of Disease==
Acute basophilic leukemia is a rare subtype of acute myeloid leukemia (AML) with primary differentiation to basophils<ref name=":0">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. IARC Press: Lyon, France, p164-165.</ref>. This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":0" />. This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms). Due to the rarity of this disease, consistent genetic diagnostic criteria have not been established. Clinical progression is often rapid and associated with poor prognosis<ref name=":1">{{Cite journal|last=Kritharis|first=Athena|last2=Brody|first2=Judith|last3=Koduru|first3=Prasad|last4=Teichberg|first4=Saul|last5=Allen|first5=Steven L.|date=2011|title=Acute basophilic leukemia associated with loss of gene ETV6 and protean complications|url=https://www.ncbi.nlm.nih.gov/pubmed/21576634|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=29|issue=21|pages=e623–626|doi=10.1200/JCO.2010.34.5710|issn=1527-7755|pmid=21576634}}</ref>.
Acute basophilic leukemia is a rare subtype of acute myeloid leukemia (AML) with primary differentiation to basophils<ref name=":0">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. IARC Press: Lyon, France, p164-165.</ref>. This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[HAEM4:Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":0" />. This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms). Due to the rarity of this disease, consistent genetic diagnostic criteria have not been established. Clinical progression is often rapid and associated with poor prognosis<ref name=":1">{{Cite journal|last=Kritharis|first=Athena|last2=Brody|first2=Judith|last3=Koduru|first3=Prasad|last4=Teichberg|first4=Saul|last5=Allen|first5=Steven L.|date=2011|title=Acute basophilic leukemia associated with loss of gene ETV6 and protean complications|url=https://www.ncbi.nlm.nih.gov/pubmed/21576634|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=29|issue=21|pages=e623–626|doi=10.1200/JCO.2010.34.5710|issn=1527-7755|pmid=21576634}}</ref>.
==Synonyms / Terminology==
==Synonyms / Terminology==